Table 3 Proportion of patients who achieved therapy effectiveness and individual criteria at 1 year of follow-up (n = 16,305)
From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Effectiveness criteria | DMARDs | TNFi ± DMARDs | Non-TNF biologics ± DMARDs | Tofacitinib ± DMARDs | ||||
|---|---|---|---|---|---|---|---|---|
Percent | 95% CI | Percent | 95% CI | Percent | 95% CI | Percent | 95% CI | |
Effective therapy (satisfied all six criteria) | 11.1 | 10.1–12.1 | 18.6 | 17.9–19.4 | 19.8 | 18.2–21.4 | 15.4 | 6.6–24.2 |
Criterion 1 High adherence | 26.6 | 25.1–28.0 | 44.0 | 43.0–44.9 | 53.3 | 51.3–55.3 | 27.7 | 16.8–38.6 |
Criterion 2 No biologic or tofacitinib switch or addition | 72.7 | 71.2–74.1 | 64.3 | 63.4–65.2 | 82.1 | 80.5–83.6 | 84.6 | 75.8–93.4 |
Criterion 3 No DMARD switch or addition | 85.3 | 84.2–86.5 | 96.1 | 95.8–96.5 | 95.5 | 94.6–96.3 | 98.5 | 95.5–100 |
Criterion 4 No increase in dose or frequency of index drug | 92.0 | 91.1–92.9 | 94.0 | 93.5–94.4 | 88.9 | 87.6–90.1 | 100.0a | – |
Criterion 5 No more than one glucocorticoid joint injection | 91.3 | 90.3–92.2 | 88.8 | 88.2–89.4 | 72.8 | 71.0–74.6 | 87.7 | 79.7–95.7 |
Criterion 6 No new/increased oral glucocorticoid dose | 81.4 | 80.2–82.7 | 83.3 | 82.6–84.1 | 78.0 | 76.3–79.7 | 76.9 | 66.7–87.2 |